help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2003-0649
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berger, A.
Right arrow Articles by Kofler, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berger, A.
Right arrow Articles by Kofler, B.
Endocrinology Vol. 145, No. 2 500-507
Copyright © 2004 by The Endocrine Society

Galanin Receptor Subtype GalR2 Mediates Apoptosis in SH-SY5Y Neuroblastoma Cells

Alexandra Berger, Roland Lang, Kerstin Moritz, Radmila Santic, Anton Hermann, Wolfgang Sperl and Barbara Kofler

Department of Pediatrics, General Hospital Salzburg (A.B., R.L., K.M., R.S., W.S., B.K.), and Department of Molecular Neurobiology and Cellular Physiology, Institute of Zoology, University of Salzburg (A.H.), A-5020 Salzburg, Austria

Address all correspondence and requests for reprints to: Dr. Barbara Kofler, Department of Pediatrics, General Hospital Salzburg, Muellner Hauptstrasse 48, A-5020 Salzburg, Austria. E-mail: b.kofler{at}lks.at.

Recently we have shown that galanin binding significantly correlates with survival in neuroblastoma patients, indicating a possible modulatory role of galanin receptors in neuroblastic tumor biology. However, the molecular mechanisms beyond this correlation have not been elucidated. Here, the cellular effects on activation of specific galanin receptor subtypes in human SH-SY5Y neuroblastoma cells were analyzed using a tetracycline-controlled expression system. Pharmacological studies confirmed the inducible expression of high affinity binding sites for galanin in SH-SY5Y cells transfected with the galanin receptors GalR1 (SY5Y/GalR1) and GalR2 (SY5Y/GalR2). Microphysiometry revealed that both receptor subtypes were able to mediate an intracellular signal upon galanin application. Interestingly, induction of receptor expression and treatment with 100 nM galanin resulted in a dramatic decrease in cell viability in SY5Y/GalR2 cells (93 ± 3%) compared with a less pronounced effect in SY5Y/GalR1 cells (19 ± 10%). The antiproliferative potency of galanin was 100-fold higher in SY5Y/GalR2 (50% effective concentration, 1.1 nM) than in SY5Y/GalR1 cells (50% effective concentration, 190 nM). Furthermore, activation of receptor expression and exposure to galanin resulted in apparent morphological changes indicative of apoptosis in SY5Y/GalR2 cells only. Induction of cell death by the apoptotic process was confirmed by poly-(ADP-ribose)-polymerase cleavage, caspase-3 activation, and the typical laddering of DNA. This study indicates that a high level of GalR2 expression is able to inhibit cell proliferation and induce apoptosis in neuroblastoma cells and therefore identifies GalR2 as a possible target for pharmacological intervention in neuroblastoma.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
T. Kanazawa, P. K. Kommareddi, T. Iwashita, B. Kumar, K. Misawa, Y. Misawa, I. Jang, T. S. Nair, Y. Iino, and T. E. Carey
Galanin Receptor Subtype 2 Suppresses Cell Proliferation and Induces Apoptosis in p53 Mutant Head and Neck Cancer Cells
Clin. Cancer Res., April 1, 2009; 15(7): 2222 - 2230.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Tofighi, B. Joseph, S. Xia, Z.-Q. D. Xu, B. Hamberger, T. Hokfelt, and S. Ceccatelli
Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2)
PNAS, February 19, 2008; 105(7): 2717 - 2722.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Santic, S. M. Schmidhuber, R. Lang, I. Rauch, E. Voglas, N. Eberhard, J. W. Bauer, S. D. Brain, and B. Kofler
Alarin is a vasoactive peptide
PNAS, June 12, 2007; 104(24): 10217 - 10222.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. P. Agaram, P. Besmer, G. C. Wong, T. Guo, N. D. Socci, R. G. Maki, D. DeSantis, M. F. Brennan, S. Singer, R. P. DeMatteo, et al.
Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors
Clin. Cancer Res., January 1, 2007; 13(1): 170 - 181.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. S. Henson, R. R. Neubig, I. Jang, T. Ogawa, Z. Zhang, T. E. Carey, and N. J. D'Silva
Galanin Receptor 1 Has Anti-proliferative Effects in Oral Squamous Cell Carcinoma
J. Biol. Chem., June 17, 2005; 280(24): 22564 - 22571.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society